Keywords: ادوکسابان; Stroke; dabigatran; rivaroxaban; apixaban; edoxaban; oral anticoagulants;
مقالات ISI ادوکسابان (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ادوکسابان; Deep Vein Thrombosis; Anticoagulant drugs; Thrombolytic therapy; Mechanical thrombolysis; Rivaroxaban; Apixaban; Edoxaban; Dabigatran; Warfarin;
Keywords: ادوکسابان; Closed-wedge high tibial osteotomy (CWHTO); Venous thromboembolism (VTE); Deep vein thrombosis (DVT); Pulmonary embolism (PE); Edoxaban;
Keywords: ادوکسابان; Antiplatelet drugs; apixaban; bleeding; dabigatran; direct oral anticoagulants; disseminated intravascular coagulation; edoxaban; liver disease; rivaroxaban; vascular abnormalities; vitamin K deficiency; warfarin;
Keywords: ادوکسابان; Absorption; Anticoagulation; Apixaban; Bariatric surgery; Biliopancreatic diversion; Bleeding; Dabigatran; Edoxaban; Efficacy; Gastrectomy; Gastric banding; Obesity; Pharmacokinetics; Rivaroxaban; Roux-en-Y; Safety; Thrombosis; Warfarin;
Keywords: ادوکسابان; Apixaban; Dabigatran; DOACs; Edoxaban; Measurement; Reversal; Rivaroxaban;
Keywords: ادوکسابان; Direct oral anticoagulant; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Randomized clinical trials;
Keywords: ادوکسابان; Idarucizumab; Andexanet alfa; DOAC; NOAC; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Antidote; Praxbind; ANNEXA-A; ANNEXA-R;
Keywords: ادوکسابان; Apixaban; Dabigatran; Direct thrombin inhibitors; Edoxaban; Factor Xa inhibitors; Rivaroxaban;
Keywords: ادوکسابان; atrial fibrillation; edoxaban; net clinical benefit; oral anticoagulation; warfarinAF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age 65 to 74 or ≥75 years, diabetes, stroke or transient ischemic attack, vascular disease, s
Keywords: ادوکسابان; Apixaban; Bleeding management; Clinical trials; Dabigatran; Direct oral anticoagulants; Edoxaban; Rivaroxaban;
Keywords: ادوکسابان; Anticoagulation; Novel oral anticoagulants; Rivaroxaban; Apixaban; Edoxaban; Dabigatran
Keywords: ادوکسابان; Anticoagulación oral; Fibrilación auricular; Dabigatran; Rivaroxaban; Apixaban; Edoxaban;
Keywords: ادوکسابان; LC-MS/MS; Direct oral anticoagulants; Coagulation tests; Chromogenic assay; Rivaroxaban; Edoxaban; Apixaban; Dabigatran;
Keywords: ادوکسابان; Tromboembolismo venoso; Dabigatrán; Rivaroxabán; Apixabán; EdoxabánVenous thromboembolism; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
Keywords: ادوکسابان; Edoxaban; warfarin; nonvalvular atrial fibrillation; stroke; systemic embolism; bleeding;
Keywords: ادوکسابان; Anciano; Fibrilación auricular no valvular; Guías; Antagonistas de la vitamina K; Dabigatran; Rivaroxaban; Apixaban; EdoxabanElderly; Nonvalvular atrial fibrillation; Guidelines; Vitamin K antagonists; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
Keywords: ادوکسابان; Elderly; Nonvalvular atrial fibrillation; Guidelines; Vitamin K antagonists; Dabigatran; Rivaroxaban; Apixaban; EdoxabanAnciano; Fibrilación auricular no valvular; Guías; Antagonistas de la vitamina K; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
Keywords: ادوکسابان; Novel oral anticoagulants; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Cost-effectiveness; Atrial fibrillationNovos anticoagulantes orais; Apixabano; Dabigatrano; Edoxabano; Rivaroxabano; Custo-efetividade; Fibrilhação auricular
Keywords: ادوکسابان; apixaban; atrial fibrillation; clinical impact; cost-effectiveness; edoxaban;
Keywords: ادوکسابان; Aspirin; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Oral anticoagulants; Pulmonary embolism; Venous thromboembolism; Venous thrombosis
Keywords: ادوکسابان; Venous thromboembolism; Cancer; New oral anticoagulants; Apixaban; Dabigatran; Rivaroxaban; Edoxaban
Keywords: ادوکسابان; Venous thromboembolism; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Warfarin;
Keywords: ادوکسابان; Atrial fibrillation; Stroke; Dabigatran; Rivaroxaban; Apixaban; Edoxaban;
Keywords: ادوکسابان; apixaban; bleeding; dabigatran; direct oral anticoagulant; edoxaban; management; pharmacology; rivaroxaban; ACS; acute coronary syndrome; AF; atrial fibrillation; ASA; acetylsalicylic acid; bid; twice daily; CrCl; creatinine clearance; CYP; cytochrome P45
Keywords: ادوکسابان; Edoxaban; resolution; left atrial appendage thrombus; atrial fibrillation
Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay
Keywords: ادوکسابان; Thrombin generation assay; Direct oral anticoagulants; DOAC adsorbent; Dabigatran; Rivaroxaban; Edoxaban; Apixaban;
Simple method for removing DOACs from plasma samples
Keywords: ادوکسابان; DOAC; Dabigatran; Apixaban; Rivaroxaban; Edoxaban; APTT; dRVVT; Lupus anticoagulant; Clotting tests; DOAC adsorbent;
The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly
Keywords: ادوکسابان; Apixaban; Atrial fibrillation; Dabigatran; Non-vitamin K antagonist oral anticoagulant; Edoxaban; Rivaroxaban;
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke
Keywords: ادوکسابان; Stroke volume; recurrent; NOAC; DOAC; direct thrombin inhibitor; dabigatran; factor Xa inhibitor; rivaroxaban; apixaban; edoxaban; warfarin;
What have we learned from real-world NOAC studies in venous thromboembolism treatment?
Keywords: ادوکسابان; Real world evidence; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Venous thromboembolism;
Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays
Keywords: ادوکسابان; aPTT; activated partial thromboplastin time; BEH; bridged ethyl hybrid; CV; coefficient of variation; DOACs; direct oral anticoagulants; DTI; direct thrombin inhibitor(s); IS; internal standard; MRM; multiple reaction monitoring mode; MS/MS; tandem mass s
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)
Keywords: ادوکسابان; Apixaban (CID: 10182969); Betrixaban (CID: 10275777) dabigatran etexilate (CID: 216210); Edoxaban (CID: 10280735); Rivaroxaban (CID: 9875401); Warfarin (CID:â54678486); Apixaban; Betrixaban; Dabigatran etexilate; Edoxaban; Rivaroxaban; Warfarin;
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial
Keywords: ادوکسابان; Anticoagulation; Atrial fibrillation; Ablation; Edoxaban; DOAC;
Non-vitamin K antagonist oral anticoagulants and the management of bleeding
Keywords: ادوکسابان; Apixaban; bleeding; dabigatran; edoxaban; NOAC; rivaroxaban;
Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay
Keywords: ادوکسابان; AE; Adverse events; aPTT; activated partial thromboplastin time; ANOVA; Analysis of variance; CI; Confidence interval; DOACs; Direct oral anticoagulants; FDA; Food and Drug Administration; FXa; Factor Xa; GLSM; Geometric least squares means; LC/MS/MS; Liq
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective
Keywords: ادوکسابان; atrial fibrillation; cost-effectiveness; decision-analytic modeling; edoxaban; factor Xa inhibitors; health economics; Markov model; Taiwan; warfarin;
Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants
Keywords: ادوکسابان; Direct Oral Anticoagulants; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Anticoagulation; Pulmonary Embolism; Deep Vein Thrombosis;
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Keywords: ادوکسابان; Anticoagulation; Atrial fibrillation; Direct oral anticoagulant; Edoxaban; Factor Xa inhibitors; Venous thromboembolism;
Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents
Keywords: ادوکسابان; Edoxaban (PubChem CID: 25022378); Clopidogrel (PubChem CID: 115366); Aspirin (PubChem CID: 2244)Arterial thrombosis; Direct factor Xa inhibitor; Edoxaban; Antiplatelet agent; Platelet procoagulant activity; Bleeding
Estudios en fase III del edoxabán
Keywords: ادوکسابان; Edoxabán; Ensayos en fase III; Eficacia; Seguridad; Fibrilación auricular no valvular; Enfermedad tromboembólica venosa; Ictus; Edoxaban; Phase-III studies; Efficacy; Safety; Nonvalvular atrial fibrillation; Venous thromboembolism; Stroke;
Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician
Keywords: ادوکسابان; novel oral anticoagulants; dabigatran; rivaroxaban; edoxaban; apixaban; direct thrombin inhibitor; factor Xa; atrial fibrillation; activated charcoal; prothrombin complex concentrates; vitamin K antagonists; warfarin; recombinant factor VIIa; idarucizumab
Dosage plasmatique de quatre anticoagulants directs par UHPLC/DAD
Keywords: ادوکسابان; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Chromatographie liquide; Extraction en phase solide; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Liquid chromatography; Solid phase extraction;
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling : ENGAGE AF–TIMI 48 Analysis
Keywords: ادوکسابان; anticoagulation; atrial fibrillation; edoxaban; falls; frailty; NOACsAF, atrial fibrillation; ARR, absolute risk reduction; CCI, Charlson Comorbidity Index; CI, confidence interval; HDER, higher dose edoxaban regimen; HR, hazard ratio; ICH, intracranial h
Clinical research studyMortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
Keywords: ادوکسابان; Anticoagulant; Bleeding; Death; Edoxaban; Factor Xa inhibitor; Hemorrhage; Warfarin;
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
Keywords: ادوکسابان; apixaban; dabigatran; edoxaban; renal dialysis; rivaroxaban; strokeACC, American College of Cardiology; AF, atrial fibrillation; AHA, American Heart Association; CI, confidence interval; CKD, chronic kidney disease; CrCl, creatinine clearance; ESRD, end-s
An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery
Keywords: ادوکسابان; direct or novel or target-specific oral anticoagulant; DOAC; NOAC; TSOAC; dabigatran; rivaroxaban; apixaban; edoxaban; betrixaban; oral surgery
Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
Keywords: ادوکسابان; Atrial fibrillation; NOAC; Dabigatran; Rivaroxaban; Apixaban; Edoxaban;
Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin
Keywords: ادوکسابان; Intrinsic pathway; Direct thrombin inhibitor; Melagatran; Activated protein C; Direct factor Xa inhibitor; Edoxaban
Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study
Keywords: ادوکسابان; Atrial fibrillation; Edoxaban; Stroke; Bleeding; Modelling; Net clinical benefit;